Terence Flynn: AI Opportunities in Healthcare

Terence Flynn: AI Opportunities in Healthcare

Artificial intelligence could help biopharmaceutical companies reduce costs as well as improve their chances of developing successful new drugs.


----- Transcript -----

Welcome to Thoughts on the Market. I'm Terence Flynn, Morgan Stanley's Head of U.S. BioPharma Research. Along with my colleagues bringing you a variety of perspectives, today, I'll focus on how artificial intelligence and machine learning can reshape the health care sector. It's Thursday, July 6th at 10 a.m. in New York.


As we've discussed on this podcast, Tech Diffusion is one of the big three themes we at Morgan Stanley Research are following this year. The other two being the Multipolar World and Decarbonization. As a quick reminder, by tech diffusion, we mean the process by which any transformative technology is adopted widely by consumers and industries.


When it comes to the healthcare sector, it's still early but we believe artificial intelligence and machine learning adoption is poised to accelerate significantly. The biopharma industry specifically is moving to unlock the potential of A.I across multiple areas, including drug discovery, clinical development, manufacturing and physician patient engagement.


We see two broad areas where A.I enabled investments in drug development could drive significant value in the biopharma space. One is direct cost savings, so think of improved R&D margins, for example. And two is increased probability of success of pipeline programs. Here we estimate that even small improvements in the probability of success could drive significant value.


Now, let me put some numbers around this. Over the past ten years, the FDA has granted 430 new drug approvals or about 43 per year. We estimate that every two and a half percentage point improvement in early stage development success rates could lead to an additional 30 new drug approvals over the course of ten years, or nearly a 10% boost. Assuming that each incremental approved drug generates over 600 million in peak sales, we estimate that 60 additional therapies approved over a ten year period would translate into an additional 70 billion in drug development and PV for the biopharma industry.


However, biopharma is not the only health care subsector that's poised to benefit from A.I.. Looking at health care services and technology, A.I represents an opportunity to drive meaningful change in efficiency in how care is delivered. A.I tools have predictive capabilities that could be used for early diagnosis and detection of disease, which could lead to improved clinical outcomes and patient experience and reduce the cost of care over time. Many health systems have already begun to migrate data from on premises to the cloud, an important step for capturing the full benefits of A.I.


We will continue to monitor further developments in health care, both near-term and long term, and will provide you with our latest analysis and insights.


Thanks for listening. If you enjoy the show, please leave us a review on Apple Podcasts and share Thoughts on the Market with a friend or colleague today.

Jaksot(1515)

Mike Wilson: U.S. Equities - Is the Worst Behind Us?

Mike Wilson: U.S. Equities - Is the Worst Behind Us?

Although economic and earnings data could be gloomy over the next month, have equity markets already discounted the bad news? Detailed analysis from Chief Investment Officer Mike Wilson.

30 Maalis 20203min

Andrew Sheets: The Critical Calls of Financial Referees

Andrew Sheets: The Critical Calls of Financial Referees

Governments and central banks face two issues: A flight to liquidity and a global economy that showed signs of fatigue even before the pandemic. For investors seeking opportunities, it’s an important distinction.

27 Maalis 20203min

Special Episode: Can $2 Trillion Flatten the Unemployment Curve?

Special Episode: Can $2 Trillion Flatten the Unemployment Curve?

As a record 3.28 million workers file for unemployment, our Chief U.S. Economist and Chief U.S. Public Policy researcher weigh potential effects from the fiscal package now before Congress.

26 Maalis 20206min

Michael Zezas: Sizing Up the Stimulus Package

Michael Zezas: Sizing Up the Stimulus Package

Congressional leaders have reached a deal on a $2 trillion stimulus bill to deal with fallout from the coronavirus crisis. Will it work? Two criteria to watch for.

25 Maalis 20202min

Mike Wilson: The Underlying Reasons for Recession

Mike Wilson: The Underlying Reasons for Recession

Mike Wilson looks beyond the coronavirus outbreak at the two key conditions which have made the markets vulnerable to a recession.

23 Maalis 20203min

Andrew Sheets: First, Improve on Uncertainty

Andrew Sheets: First, Improve on Uncertainty

On this episode, Chief Cross-Asset Strategist Andrew Sheets says that the 4%+ swings in equities markets have made investors skeptical about jumping back in. More U.S. testing could help.

20 Maalis 20203min

Andrew Sheets: Why We Think Risk/Reward Is Improving

Andrew Sheets: Why We Think Risk/Reward Is Improving

Although the sell-off may not be over and the global economy has tough days ahead, a growing number of factors suggest that risk/reward in markets may be getting better.

19 Maalis 20203min

Special Episode: Imagining the Shape of Recovery

Special Episode: Imagining the Shape of Recovery

As central banks and governments weigh a litany of stimulus efforts, what could the journey to economic recovery look like? Our Chief U.S. Economist and Head of U.S. Public Policy Research sum up the debates.

18 Maalis 20207min

Suosittua kategoriassa Liike-elämä ja talous

sijotuskasti
psykopodiaa-podcast
mimmit-sijoittaa
rss-rahapodi
rss-rahamania
herrasmieshakkerit
ostan-asuntoja-podcast
pari-sanaa-lastensuojelusta
rss-lahtijat
oppimisen-psykologia
lakicast
taloudellinen-mielenrauha
rss-neuvottelija-sami-miettinen
yrittaja
rss-startup-ministerio
rss-myynti-ei-ole-kirosana
hyva-paha-johtaminen
rss-myyntikoulu
rss-karon-grilli
rss-seuraava-potilas